Evidence map›Paper›PMID 42818751›Full record

ArticlebioRxiv : the preprint server for biology2026

Alveolar Cytochrome P450 Mediates Butylated Hydroxytoluene-Induced Electrophilic Injury and Apoptosis.

Michael T Forrester, Katherine M Harbaugh, Naoya Miyashita, Kyoshiro Tsuge, Rhianna Lee-Ferris, Jeremy M Morowitz, Aleksandra Tata, Robert M Tighe, Matthew W Foster, Christine E Eyler and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Michael T ForresterDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham NC.ORCID 0009-0007-4665-4164
Katherine M HarbaughDepartment of Radiation Oncology, Duke University School of Medicine, Durham NC.ORCID 0009-0008-7233-5834
Naoya MiyashitaDepartment of Cell Biology, Duke University School of Medicine, Durham NC.ORCID 0000-0002-2464-5167
Kyoshiro TsugeDepartment of Cell Biology, Duke University School of Medicine, Durham NC.ORCID 0000-0001-9419-7331
Rhianna Lee-FerrisDepartment of Cell Biology, Duke University School of Medicine, Durham NC.ORCID 0000-0003-2039-1304
Jeremy M MorowitzDepartment of Cell Biology, Duke University School of Medicine, Durham NC.ORCID 0000-0002-3117-6485
Aleksandra TataDepartment of Cell Biology, Duke University School of Medicine, Durham NC.ORCID 0000-0003-3270-0485
Robert M TigheDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham NC.ORCID 0000-0002-3465-9861
Matthew W FosterDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham NC.ORCID 0000-0003-0212-2346
Christine E EylerDepartment of Radiation Oncology, Duke University School of Medicine, Durham NC.ORCID 0000-0001-6113-2478
Purushothama Rao TataDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University School of Medicine, Durham NC.ORCID 0000-0003-4837-0337

Funding

Molecular control of a novel transitional cell state in alveolar regenerationR01HL153375 · NHLBI · DUKE UNIVERSITY · PI Purushothama Rao Tata · 2020 to 2026
$3.4M
Cellular crosstalk and molecular mechanisms in the initiation and progression of pulmonary fibrosisR01HL160939 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2022 to 2025
$2.1M
Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platformK08CA263300 · NCI · DUKE UNIVERSITY · PI Christine Elissa Eyler · 2022 to 2026
$1.2M
Role of Protein S-Palmitoylation in TGFbeta Signaling and Fibrotic Lung DiseaseK08HL181195 · NHLBI · DUKE UNIVERSITY · PI Michael T Forrester · 2025 to 2026
$331k
NCI NIH HHS K08 CA263300NHLBI NIH HHS K08 HL181195NHLBI NIH HHS R01 HL153375NHLBI NIH HHS R01 HL160939
6 · The paper itself

Abstract

Butylated hydroxytoluene (BHT) is a synthetic phenolic antioxidant utilized as a preservative in many products from foods to cosmetics. Population-based studies have detected BHT in the vast majority (>90%) of human specimens (serum, urine, fingernails) as well as home dust samples. Thus, BHT constitutes a ubiquitous environmental contaminant without obvious adverse health effects to humans. In contrast, exposure of mice to a single intraperitoneal dose of BHT triggers distal epithelial damage including loss of gas-exchanging alveolar type 1 epithelial cells, thus providing an invaluable tool to study alveolar repair and transient fibrosis. Presently, the molecular basis of BHT lung toxicity remains unknown. To address this, mouse lung single cell transcriptomic data were used to identify cytochrome P450 2B10 (CYP2B10) in AT1 cells as a BHT-activating enzyme. In cell culture systems, expression of CYP2B10 leads to marked BHT sensitization consistent with bioactivation of BHT into a toxic quinone methide. Targeted and proteome-wide experiments identify BHT-induced protein alkylation, DNA damage response, stress kinase activation and intrinsic apoptosis in a CYP2B10-dependent manner. Structure-activity relationship studies reveal the necessity of

Indexed as

alkylationalveoliBHTbutylated hydroxytolueneCYP450Cytochrome P450DNA damagefibrosisquinone methidestress signalingsynthetic phenolic antioxidant

Identifiers

PMID42818751
PMCPMC13622689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.